Overview
Montis Biosciences develops next-generation therapeutics that harness the dual biology of complement C1q by simultaneously targeting the complement and myeloid axes. The company's pipeline targets neuroinflammatory diseases, with a lead program in Guillain-Barré syndrome. Montis is headquartered in Leuven, Belgium, and is supported by investors including DROIA Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB.
Key people
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.